Alnylam Pharmaceuticals | ALNY - EPS Earnings Per Share


Alnylam Pharmaceuticals reported $16.26 in EPS Earnings Per Share for its fiscal quarter ending in September of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q3 Sep/2026 16.26 1.97 2.90 Oct/29
FY2026Q2 Jun/2026 1.84 1.61 0.32 Jul/30
FY2026Q1 Mar/2026 1.99 0.99 -0.01 Apr/30
FY2025Q4 Dec/2025 1.25 1.27 0.06 Feb/12
FY2025Q3 Sep/2025 2.90 0.27 -0.50 Oct/30




Eps Change Date
Acadia Pharmaceuticals USD 0.31 0.13 Sep/2026
Agios Pharmaceuticals USD -1.09 0.6 Sep/2026
Alnylam Pharmaceuticals USD 16.26 14.42 Sep/2026
Amgen USD 6.45 0.16 Sep/2026
Arrowhead Research USD -5.11 3.75 Sep/2026
BioCryst Pharmaceuticals USD 0.3 0.87 Jun/2026
BioMarin Pharmaceutical USD 0.23 0.97 Sep/2026
Incyte USD -3.6 6.69 Sep/2026
Ionis Pharmaceuticals USD 0.66 1.35 Sep/2026
Moderna USD 0.38 2.35 Sep/2026
Neurocrine Biosciences USD 3.29 0.44 Sep/2026
Novartis USD 0.63 1.36 Sep/2026
PTC Therapeutics USD -0.62 1.54 Sep/2026
Regeneron Pharmaceuticals USD 20.07 5.78 Sep/2026
Sangamo BioSciences USD -0.18 0.1 Jun/2024
Sanofi EUR 0.14 2.02 Jun/2026
Sarepta Therapeutics USD 0.13 0.51 Sep/2026
Takeda JPY 116.95 45.3 Sep/2026
Tectonic Therapeutic USD -1.18 0.17 Jun/2026
Ultragenyx Pharmaceutical USD -1.16 0.26 Sep/2026
Vertex Pharmaceuticals USD 4.76 0.03 Sep/2026
Xencor USD 0.5 0.79 Sep/2026